COMMUNIQUÉS West-GlobeNewswire

Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)

11/11/2024 - 22:35

LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member of the Roche Group, for ITOVEBI ™ ( [...]

DBV Technologies Announces Plan to Implement ADS Ratio Change

11/11/2024 - 22:30

Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage [...]

DBV Technologies annonce son intention de modifier le ratio d'ADS

11/11/2024 - 22:30

Châtillon, France, le 11 novembre (22 :30 CET) 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP:23306J200), [...]

Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

11/11/2024 - 22:15

GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]

Sienna Senior Living Inc. Reports Strong Third Quarter 2024 Financial Results and Continues on its Growth Path

11/11/2024 - 22:15

MARKHAM, Ontario, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2024. The [...]

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

11/11/2024 - 22:05

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management [...]

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

11/11/2024 - 22:05

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

11/11/2024 - 22:05

Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering [...]

Regeneron Announces Investor Conference Presentations

11/11/2024 - 22:05

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/11/2024 - 22:05

Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified [...]

HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

11/11/2024 - 22:05

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good [...]

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

11/11/2024 - 22:05

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid [...]

IO Biotech Announces Participation in Upcoming Investor Conferences

11/11/2024 - 22:05

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® [...]

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/11/2024 - 22:05

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]

Nanox to Report Third Quarter and Financial Results on November 21, 2024

11/11/2024 - 22:05

PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

11/11/2024 - 22:05

FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for [...]

Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering

11/11/2024 - 22:05

Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Monrovia, CA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based [...]

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

11/11/2024 - 22:05

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control [...]

Stereotaxis Reports 2024 Third Quarter Financial Results

11/11/2024 - 22:02

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third [...]